Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.
Elledge
R M
RM
Division of Medical Oncology, University of Texas Health Science Center at San Antonio 78284, USA.
Gray
R
R
Mansour
E
E
Yu
Y
Y
Clark
G M
GM
Ravdin
P
P
Osborne
C K
CK
Gilchrist
K
K
Davidson
N E
NE
Robert
N
N
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D009363:Neoplasm Proteins / Q000032:analysis*; D011237:Predictive Value of Tests; D011241:Prednisone / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012306:Risk; D016019:Survival Analysis; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53; D003520:Cyclophosphamide; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate